|
ATHA | Athira Pharma, Inc. |
|
|
ATHA | Athira Pharma, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 2.62 |
| Leverage | 33.23% |
| Market Cap | $ 22.0m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -108.4m |
| Margin | -2131.52% |
Athira Pharma, Inc., a late-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. The company is headquartered in Bothell, Washington.